Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday.
The company reported a second-quarter 2025 adjusted earnings of 32 cents, down from 56 cents a year ago. Analysts estimated a loss of 79 cents.
The company reported quarterly sales of $773.69 million, up 17% year over year, beating the consensus of $638.55 million.
Alnylam Pharmaceuticals achieved global net product revenues for Amvuttra and Onpattro for the second quarter of $492 million and $53 million.
The company achieved global net product revenues for Givlaari and Oxlumo for the second quarter of $81 million and $47 million.
Alnylam raised its fiscal 2025 sales guidance from $2.7 billion-$3 billion to $3.3 billion-$3.55 billion compared to the consensus of $2.89 billion.
Chardan Research and William Blair have both issued positive outlooks on Alnylam following the second-quarter results. Chardan Research stated that the launch of Amvuttra for ATTR-CM (Transthyretin Amyloid Cardiomyopathy) …